⏳ Fetching live dividend data...
Home › Calculator › MRTX Dividend Calculator 2026
Mirati Therapeutics, Inc. · NASDAQ
Price: $58.70 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in MRTX → $14.0K in 10 years · $38.39/month
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open MRTX position with:
Real after-tax yield depends on where you live and how you hold MRTX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 3.41% | 0.61% | $341 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2.90% | 0.10% | $290 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 2.73% | -0.07% | $273 / yr |
| 🇬🇧 UK ISA | 0% | 3.41% | 0.61% | $341 / yr |
| 🇬🇧 UK Taxable | 8.75% | 3.11% | 0.31% | $311 / yr |
| 🇨🇦 TFSA | 0% | 3.41% | 0.61% | $341 / yr |
| 🇨🇦 CA Taxable | 25% | 2.56% | -0.24% | $256 / yr |
| 🇦🇺 Super (pension) | 15% | 2.90% | 0.10% | $290 / yr |
| 🇦🇺 AU Taxable | 30% | 2.39% | -0.41% | $239 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2.51% | -0.29% | $251 / yr |
| 🇫🇷 FR Taxable | 30% | 2.39% | -0.41% | $239 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
MRTX pays quarterly — 4 times per year. Next ex-div: TBD.
How MRTX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for MRTX sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2024-01-23 | 1,413,475 | $0.00 | $1.4K | ||
| D-Return | 2024-01-23 | 30,518 | $0.00 | $31.00 | ||
| D-Return | 2024-01-23 | 4,162 | $58.00 | $241.4K | ||
| D-Return | 2024-01-23 | 5,252 | — | — | ||
| D-Return | 2024-01-23 | 7,520 | $45.66 | $343.4K | ||
| D-Return | 2024-01-23 | 6,808 | — | — | ||
| D-Return | 2024-01-23 | 4,444 | — | — | ||
| D-Return | 2024-01-23 | 6,808 | — | — | ||
| D-Return | 2024-01-23 | 7,520 | $45.66 | $343.4K | ||
| D-Return | 2024-01-23 | 43,073 | $58.00 | $2.50M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the MRTX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Mirati Therapeutics, Inc. (MRTX) is currently trading at $58.70, 74% below its 52-week high. The current dividend yield is 3.41% based on an annual payout of $2.00 per share.
Mirati Therapeutics, Inc. (MRTX) is a healthcare stock currently trading at $58.70 with a dividend yield of 3.41%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →